Brand Reference: Nuvigil
| Metric | Verified Benchmark | Source |
|---|---|---|
| Armodafinil (Isolated R-Enantiomer) RxNorm Concept ID | 686430 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.3600 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $264.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $15.60 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $21.00 / mo | 26 Zero-PHI Verified Patient Logs |
Isolates the slower-clearing R-(-)-enantiomer of modafinil, eliminating rapid early-day S-enantiomer decay so plasma concentrations remain 35%–40% higher from hours 6 to 14 post-dose than milligram-equivalent racemic modafinil.
Classified under Pure R-Modafinil Late-Afternoon Sustained Wakefulness Promoter (Rx), Armodafinil (Isolated R-Enantiomer) exhibits a $248.40/month gap between standard U.S. retail cash counters ($264.00) and verified direct-to-patient routing ($15.60) anchored to $0.3600 CMS unit cost.
Pharmacokinetic profiling of Armodafinil (Isolated R-Enantiomer) demonstrates an elimination half-life of 15 hours monophasic with > 85% oral systemic bioavailability; clearance proceeds via amide hydrolysis and cyp3a4 induction / cyp2c19 inhibition, reaching clinical onset within 1.5–2 hours fasting.
Titration schedules for Armodafinil (Isolated R-Enantiomer) (150 mg PO early QAM → 250 mg PO early QAM) require excluding prior modafinil hypersensitivity or sjs rash; unprotected reliance on cyp3a4 oral contraceptives; real-world patient logs highlight late-evening alertness (21% of reports), headache (19% of reports), xerostomia (11% of reports) alongside a 90.10% Worth-It consensus.
Across 26 verified cash-pay logs, Armodafinil (Isolated R-Enantiomer) achieves a 90.10% Worth-It rating with out-of-pocket spend averaging $21.00/mo versus $264.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 150 mg PO early QAM for Armodafinil (Isolated R-Enantiomer); monthly out-of-pocket dropped to $13.73 compared with $264.00 retail.
Completed 10 weeks on Armodafinil (Isolated R-Enantiomer) (250 mg PO early QAM). Zero notable side effects on steady dosing.
Consistent biomarker response on 150 mg PO early QAM Armodafinil (Isolated R-Enantiomer) sourced via TeleMed ($18.10/mo cash pay without insurance prior authorization).